Tsao CW, Aday AW, Almarzooq ZI, Alonso A, Beaton AZ, Bittencourt MS, et al. Heart disease and stroke statistics-2022 update: a report from the American Heart Association. Circulation. 2022;145(8):e153–639.

PubMed  Article  Google Scholar 

Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849–60.

PubMed  Article  Google Scholar 

Gaziano JM, Brotons C, Coppolecchia R, Cricelli C, Darius H, Gorelick PB, et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet. 2018;392(10152):1036–46.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Bowman L, Mafham M, Wallendszus K, Stevens W, Buck G, Barton J, et al. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018;379(16):1529–39.

CAS  PubMed  Article  Google Scholar 

Mahmoud AN, Gad MM, Elgendy AY, Elgendy IY, Bavry AA. Efficacy and safety of aspirin for primary prevention of cardiovascular events: a meta-analysis and trial sequential analysis of randomized controlled trials. Eur Heart J. 2019;40(7):607–17.

CAS  PubMed  Article  Google Scholar 

Meschia JF, Bushnell C, Boden-Albala B, Braun LT, Bravata DM, Chaturvedi S, et al. Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45(12):3754–832.

PubMed  PubMed Central  Article  Google Scholar 

Davidson KW, Barry MJ, Mangione CM, Cabana M, Chelmow D, Coker TR, et al. Aspirin use to prevent cardiovascular disease: US Preventive Services Task Force recommendation statement. JAMA. 2022;327(16):1577–84.

PubMed  Article  Google Scholar 

The International Stroke Trial (IST). a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke International Stroke Trial Collaborative Group. Lancet. 1997;349(9065):1569–81.

Article  Google Scholar 

CAST. randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke CAST (Chinese Acute Stroke Trial) Collaborative Group. Lancet. 1997;349(9066):1641–9.

Article  Google Scholar 

Chen ZM, Sandercock P, Pan HC, Counsell C, Collins R, Liu LS, et al. Indications for early aspirin use in acute ischemic stroke : a combined analysis of 40 000 randomized patients from the Chinese acute stroke trial and the international stroke trial On behalf of the CAST and IST collaborative groups. Stroke. 2000;31(6):1240–9.

CAS  PubMed  Article  Google Scholar 

Kay R, Wong KS, Yu YL, Chan YW, Tsoi TH, Ahuja AT, et al. Low-molecular-weight heparin for the treatment of acute ischemic stroke. N Engl J Med. 1995;333(24):1588–93.

CAS  PubMed  Article  Google Scholar 

McCarthy ST, Turner J. Low-dose subcutaneous heparin in the prevention of deep-vein thrombosis and pulmonary emboli following acute stroke. Age Ageing. 1986;15(2):84–8.

CAS  PubMed  Article  Google Scholar 

Coull BM, Williams LS, Goldstein LB, Meschia JF, Heitzman D, Chaturvedi S, et al. Anticoagulants and antiplatelet agents in acute ischemic stroke: report of the Joint Stroke Guideline Development Committee of the American Academy of Neurology and the American Stroke Association (a division of the American Heart Association). Stroke. 2002;33(7):1934–42.

CAS  PubMed  Article  Google Scholar 

Zinkstok SM, Roos YB. Early administration of aspirin in patients treated with alteplase for acute ischaemic stroke: a randomised controlled trial. Lancet. 2012;380(9843):731–7.

CAS  PubMed  Article  Google Scholar 

Liu J, Hu X, Wang Y, Guan X, Chen J, Liu H. The safety and effectiveness of early anti-platelet therapy after alteplase for acute ischemic stroke: a meta-analysis. J Clin Neurosci. 2021;91:176–82.

CAS  PubMed  Article  Google Scholar 

Jeong HG, Kim BJ, Yang MH, Han MK, Bae HJ, Lee SH. Stroke outcomes with use of antithrombotics within 24 hours after recanalization treatment. Neurology. 2016;87(10):996–1002.

CAS  PubMed  Article  Google Scholar 

Awtry EH, Loscalzo J. Aspirin Circulation. 2000;101(10):1206–18.

CAS  PubMed  Article  Google Scholar 

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Bmj. 2002;324(7329):71–86.

Kleindorfer DO, Towfighi A, Chaturvedi S, Cockroft KM, Gutierrez J, Lombardi-Hill D, et al. 2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association/American Stroke Association. Stroke. 2021;52(7):e364–467.

PubMed  Article  Google Scholar 

Gasparyan AY, Watson T, Lip GY. The role of aspirin in cardiovascular prevention: implications of aspirin resistance. J Am Coll Cardiol. 2008;51(19):1829–43.

CAS  PubMed  Article  Google Scholar 

Lee M, Saver JL, Hong KS, Rao NM, Wu YL, Ovbiagele B. Antiplatelet regimen for patients with breakthrough strokes while on aspirin: a systematic review and meta-analysis. Stroke. 2017;48(9):2610–3.

PubMed  Article  Google Scholar 

Sangkuhl K, Klein TE, Altman RB. Clopidogrel pathway. Pharmacogenet Genomics. 2010;20(7):463–5.

CAS  PubMed  PubMed Central  Article  Google Scholar 

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.Lancet. 1996;348(9038):1329-39

Ringleb PA, Bhatt DL, Hirsch AT, Topol EJ, Hacke W. Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events. Stroke. 2004;35(2):528–32.

CAS  PubMed  Article  Google Scholar 

Sacco RL, Diener HC, Yusuf S, Cotton D, Ounpuu S, Lawton WA, et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med. 2008;359(12):1238–51.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Paciaroni M, Ince B, Hu B, Jeng JS, Kutluk K, Liu L, et al. Benefits and risks of clopidogrel vs. aspirin monotherapy after recent ischemic stroke: a systematic review and meta-analysis. Cardiovasc Ther. 2019;2019:1607181.

PubMed  PubMed Central  Article  Google Scholar 

McDonough CW, McClure LA, Mitchell BD, Gong Y, Horenstein RB, Lewis JP, et al. CYP2C19 metabolizer status and clopidogrel efficacy in the Secondary Prevention of Small Subcortical Strokes (SPS3) study. J Am Heart Assoc. 2015;4(6):e001652.

PubMed  PubMed Central  Article  Google Scholar 

Jia DM, Chen ZB, Zhang MJ, Yang WJ, Jin JL, Xia YQ, et al. CYP2C19 polymorphisms and antiplatelet effects of clopidogrel in acute ischemic stroke in China. Stroke. 2013;44(6):1717–9.

CAS  PubMed  Article  Google Scholar 

Pan Y, Chen W, Xu Y, Yi X, Han Y, Yang Q, et al. Genetic polymorphisms and clopidogrel efficacy for acute ischemic stroke or transient ischemic attack: a systematic review and meta-analysis. Circulation. 2017;135(1):21–33.

CAS  PubMed  Article  Google Scholar 

Harker LA, Kadatz RA. Mechanism of action of dipyridamole. Thromb Res Suppl. 1983;4:39–46.

CAS  PubMed  Article  Google Scholar 

The European Stroke Prevention Study (ESPS). Principal end-points The ESPS Group. Lancet. 1987;2(8572):1351–4.

Google Scholar 

Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study 2 Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996;143(1–2):1–13.

CAS  PubMed  Article  Google Scholar 

Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet. 2006;367(9523):1665–73.

CAS  PubMed  Article  Google Scholar 

Verro P, Gorelick PB, Nguyen D. Aspirin plus dipyridamole versus aspirin for prevention of vascular events after stroke or TIA: a meta-analysis. Stroke. 2008;39(4):1358–63.

CAS  PubMed  Article  Google Scholar 

Douen AG, Medic S, Sabih M, Pageau N, Shuaib A. Titrated initiation of acetylsalicylic acid-dipyridamole therapy reduces adverse effects and improves tolerance in patients with stroke. J Stroke Cerebrovasc Dis. 2008;17(6):356–9.

PubMed  Article  Google Scholar 

Capodanno D, Dharmashankar K, Angiolillo DJ. Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y12 receptor antagonist. Expert Rev Cardiovasc Ther. 2010;8(2):151–8.

CAS  PubMed  Article  Google Scholar 

Bonaca MP, Goto S, Bhatt DL, Steg PG, Storey RF, Cohen M, et al. Prevention of stroke with ticagrelor in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54 (prevention of cardiovascular events in patients with prior heart attack using ticagrelor compared to placebo on a background of aspirin-thrombolysis in myocardial infarction 54). Circulation. 2016;134(12):861–71.

CAS  PubMed  Article  Google Scholar 

Johnston SC, Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, et al. Ticagrelor versus aspirin in acute stroke or transient ischemic attack. N Engl J Med. 2016;375(1):35–43.

CAS  PubMed  Article  Google Scholar